Login
$ADMA
$13.40 -$0.07 (0.52%) After hours

$ADMA 8-K SEC Filings

Filed On Filing
04 Nov 2026 8-K: Results of Operations and Financial Condition

3Q 2026 Total Revenue of $141.1 Million, Increasing 5% Year-over-Year

05 Aug 2026 8-K: Results of Operations and Financial Condition

2Q 2026 Total Revenue of $124.4 Million, Increasing 2% Year-over-Year

02 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

ADMA Biologics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) on June 2, 2026. At the Annual Meeting, the following matters were submitted to a vote of stockholders:

06 May 2026 8-K: Results of Operations and Financial Condition

1Q 2026 Total Revenue of $114.5 Million, Flat Year-Over-Year

04 May 2026 8-K: Other Events

ADMA Biologics Announces FDA Approval to Expand the Label for ASCENIVTM to Include Pediatric Immune Compromised Patients Two Years of Age and Older

27 Mar 2026 8-K: Regulation FD Disclosure

Short seller’s Characterization of ASCENIV’s Competitive Position Reflects Blatant Misunderstanding of ADMA’s Business and Its Role as Late-line Therapy for Patients Who are Immune Compromised and Therefore, May Not Respond to Vaccines

02 Mar 2026 8-K: Regulation FD Disclosure; Other Events

ADMA Biologics Announces $125 Million Accelerated Share Repurchase with JPMorgan as Part of a Planned $200 Million 2026 Total Share Repurchase Initiative

25 Feb 2026 8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation

FY 2025 Total Revenue of $510 Million, Representing 20% Year-Over-Year Growth

12 Jan 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

ADMA Biologics Realizing the Potential of Specialty Biologicswith Groundbreaking Immunotechnology January 2026 NASDAQ: ADMA

05 Nov 2025 8-K: Results of Operations and Financial Condition

3Q 2025 Adjusted EBITDA(1) of $58.7 Million, a 29% YoY Increase

06 Aug 2025 8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +2 more

Exhibit B-1 – U.S. Tax Compliance Certificate (For Foreign Lenders That Are Not Partnerships For U.S. Federal Income Tax Purposes)

04 Jun 2025 8-K: Submission of Matters to a Vote of Security Holders

ADMA Biologics, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”) on June 4, 2025. At the Annual Meeting, the following matters were submitted to a vote of stockholders:

07 May 2025 8-K: Results of Operations and Financial Condition; Other Events

1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue(1) of $118.6 Million), a 40% YoY Increase

28 Apr 2025 8-K: Other Events

Approval Supports Revenue Growth and Margin Expansion Opportunity, and Substantially Increases Peak Production Output Capacity

03 Mar 2025 8-K: Results of Operations and Financial Condition

FY 2024 GAAP Net Income of $197.7 Million, Including an $84.3 Million Valuation Allowance Tax Benefit

21 Feb 2025 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

13 Jan 2025 8-K: Regulation FD Disclosure

ADMA Biologics Realizing the Potential of Specialty Biologicswith Groundbreaking Immunotechnology January 2025 NASDAQ: ADMA

13 Jan 2025 8-K: Results of Operations and Financial Condition

FY 2024 Preliminary Unaudited Total Revenue of Approximately $417-425 Million, Exceeding Previous Guidance of $415 Million

02 Jan 2025 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

20 Dec 2024 8-K: Other Events

Cash on Hand Utilized to Repay $30 Million of Senior Secured Term Loan Facility to Ares Capital

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support